This article has Open Peer Review reports available.
Robot-assisted sacral tumor resection: a preliminary study
- Junqiang Yin†1,
- Hui Wu†2,
- Jian Tu†1,
- Changye Zou1,
- Gang Huang1,
- Xianbiao Xie1,
- Yulong He2Email author and
- Jingnan Shen1Email author
© The Author(s). 2018
Received: 29 November 2017
Accepted: 8 May 2018
Published: 6 June 2018
Few studies have been done on robot-assisted sacral surgery. This study aims to evaluate the outcomes of seven patients with benign sacral or presacral tumors treated with a robotic surgical system at a single center.
All patients with benign sacral or presacral tumors who underwent transperitoneal resection (between June 2015 and June 2016) using the da Vinci Si HD robotic surgical system (Intuitive Surgical Inc.) were included in this retrospective study.
Seven patients with a mean age of 43.8 years (range: 22- 62 years) were included in this study. The operation time ranged from 60 to 335 min. Five out of these seven patients with presacral tumor underwent complete tumor resection by the da Vinci robotic surgical system, with a median blood loss of 52 ml. The other patients underwent excision of the presacral tumor by the da Vinci robotic surgical system, followed by a posterior approach, with a median blood loss of 675 ml. The histological diagnosis was schwannoma of the sacral nerve in five cases (71.5%). The other two cases were chordoma and solitary fibroma of the sacrum, respectively. No perioperative or postoperative complications were encountered. The average hospitalization stay was 5.7 days. No recurrences were found at follow-up 24 to 31 months later.
Robot-assisted minimally invasive sacral surgery can provide precise dissection of the tissue under a perfect view. It is a technically feasible procedure that is associated with minimal blood loss, fewer injuries and short hospitalization. It is particularly suitable for presacral benign tumors.
Primary tumors originated from sacrum or retraperitioneal area are rare. Most of them are benign or low-grade malignancies, such as chondrosarcoma and schwannoma [1, 2]. The resection of the tumor was one of the most important treatments for primary malignant sacral tumors, which could be performed using anterior, posterior, lateral and combined surgical approaches. The treatment of primary sacral tumors can be challenging because of the complex surrounding anatomical structures and the large size of the tumor . The da Vinci surgical system is widely used in gastrointestinal surgery, urology and gynecological surgery, as it can provide the following advantages [4–6]. It can provide 3D vision and visual magnification (up to 15- times), which can promote more precise resection. Additionally, the da Vinci surgical system consists of three or four robotic arms, mimicking human wrist movements, with a high degree of freedom. However, there is no report about the performance of the da Vinci surgical system in the resection of sacral tumor.
We aimed to investigate the feasibility and efficiency of the da Vinci surgical system in the resection of sacral tumors.
Patients with a sacral or presacral tumor who were treated using da Vinci surgical system at the First Affiliated Hospital of Sun Yat-sen University between June 2015 and January 2016 were enrolled in this retrospective study. Written informed consent to participate in the study was obtained from participants. This study was approved by the Institutional Ethical Board of the First Affiliated Hospital of Sun Yat-sen University.
The criteria for case inclusion were as follows: (1) presence of a tumor located in sacral or pre-sacral area; (2) operated by da Vinci surgical system. Patients with previous sacral or presacral surgery history were excluded following a discussion. Patients without completed follow-up information were excluded.
Surgical treatment procedure
Clinical assessment, including a thorough history, physical examination, digital rectal examination, routine blood tests, chest X-ray, computerized tomography, magnetic resonance imaging of the pelvis and needle biopsy, was completed for all patients before robotic surgery.
Data on peri-operative outcomes, operation time, blood loss, time to eating liquid, hospitalization, cost and complications were recorded. Data on post-operative outcomes, the function assessment (motor and sensory function assessment), tumor recurrence and metastasis (X ray and MRI) were examined every 3 months for Years 1 and 2, every 6 months for Years 3 to 5 and yearly thereafter, as our previous studies described .
Clinical characteristic of patients
Tumor size (cm3)a
Operative time (min)
Blood loss (ml)
superior rectal artery
No perioperative complications were found among these seven patients. No blood transfusions were administered to these patients during perioperative and postoperative period. The average hospitalization date was 5.7 days, with an average cost of 61,000 yuan (RMB). There were no fever, wound infestion, secondary haemorrage, ileus and leakage among these seven patients. No patient was lost of follow up in this study. No motor or sensory dysfunction of lower extremity was assessed in these patients. There has no evidence of recurrence during the follow-up period of 24 to 31 months after surgery.
The incidence of sacral tumor is low. It is relatively hard for surgeons to accumulate much experience in the resection of sacral tumors. Therefore, it is of great importance to summarize the surgical outcomes of new technology in the treatment of sacral tumor. The majority of sacral tumors are primary, including chordoma, schwannoma and giant cell tumor. Surgical treatment remains as the optimal choice for primary malignant sacral tumors. As for benign or low-malignancy sacral tumors when aggravating symptoms or enlargement of tumors occurs during the clinical follow-up, surgery should be taken into consideration However, the complicated anatomical structure, narrow space for operation in the pelvis and abundant presacral vessels make the treatment of sacral tumors extremely challenging [8–10].
In our center, patients with a large mass in the sacrum usually receive hypogastric artery ligation and isolation using the anterior approach, followed by the excision of the tumor through posterior approach. This strategy could provide enough margins for excision and safety related for bleeding from tumor. However, it would increase the duration of the operation and surgical stress for patients. Several studies have reported the use of a laparoscope to ligate the hypogastric artery and isolate the presacral mass [11–13]. The magnifying function of the laparoscope allows for an en bloc resection without damaging the tumor. But, it is still inconvenient for surgeons to separate related tissue and ligate blood vessels, as laparoscope arms are lack of flexibility in the narrow and deep cavity. The robotic surgical system could provide visual magnification and a high degree of freedom for surgeons. However, no studies have reported the use of the robotic surgical system in the excision of sacral and presacral tumor.
The da Vinci surgical system is widely used in gastrointestinal surgery, urology and gynecological surgery. Therefore, we tried to utilize the robotic surgical system in the treatment of sacral tumor.
According to our experience, the use of the da Vinci surgical system in the treatment of sacral tumors, especially presacral benign tumors, is feasible. We chose the supine position with four trocars to build the robotic surgical system. As these five patients were female, the suspension of uterus was taken to expand the field of vision. Three of the five patients underwent total tumor resection using the robotic surgical system. The average operation time was 83.3 min, with blood loss amount of 60 ml for these three patients. This cost less average operative time and less bold loss compared with patients with presacral schwannoma received laparoscopic surgery . The blood loss was much less than that associated with open surgery . Additionally, it could shorten the recovery time for patients. For the other two patients, the robotic surgical system was used to separate organs close to the tumor, which made the resection of the tumor safe through a posterior approach.
Additionally, a multidisciplinary team including surgeons from musculoskeletal oncology, gastrointestinal and urological departments wan strongly recommended to perform robot-assisted surgery for patients with sacral or presacral tumors. However, this study still contained some limitations. The major one was that it was a retrospective study with limitation of enrolled patient number. It restricted the power of our analysis and conclusion. The robot-assisted minimally invasive sacral surgery should be further studies in prospective cohort with more patients included.
Robot-assisted minimally invasive sacral surgery is a technically feasible and efficent procedure that is associated with minimal blood loss, fewer injuries and short hospitalization. It is particularly suitable for presacral benign tumors.
This study was supported by grants from the National Natural Science Foundation of China (81201388 to Jingnan Shen).
Availability of data and materials
All data generated during this study are included in this published article. The datasets used during the current study available from the corresponding author on reasonable request.
JY and HW contributed to manuscript drafting and interpretation of data. JT contributed to collation and disposal of data, revised manuscript preparation. CZ contributed to patients’ follow up. GH and XX contributed to data collation and analysis and patient’s treatment. YH and JS contributed to patient’s treatment, conception and design of the study and manuscript submission. All authors have read and approved the final manuscript.
Ethics approval and consent to participate
Written informed consent for participation in the study was obtained from participants. This study was approved by the Institutional Ethical Board of the First Affiliated Hospital of Sun Yat-sen University.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- York JE, Kaczaraj A, Abi-Said D, Fuller GN, Skibber JM, Janjan NA, Gokaslan ZL. Sacral chordoma: 40-year experience at a major cancer center. Neurosurgery. 1999;44(1):74–9. discussion 79-80View ArticlePubMedGoogle Scholar
- Kayani B, Hanna SA, Sewell MD, Saifuddin A, Molloy S, Briggs TW. A review of the surgical management of sacral chordoma. Eur J Surg Oncol. 2014;40(11):1412–20.View ArticlePubMedGoogle Scholar
- Varga PP, Szoverfi Z, Lazary A. Surgical treatment of primary malignant tumors of the sacrum. Neurol Res. 2014;36(6):577–87.View ArticlePubMedGoogle Scholar
- Corcione F, Esposito C, Cuccurullo D, Settembre A, Miranda N, Amato F, Pirozzi F, Caiazzo P. Advantages and limits of robot-assisted laparoscopic surgery: preliminary experience. Surg Endosc. 2005;19(1):117–9.View ArticlePubMedGoogle Scholar
- Rodriguez-Sanjuan JC, Gomez-Ruiz M, Trugeda-Carrera S, Manuel-Palazuelos C, Lopez-Useros A, Gomez-Fleitas M. Laparoscopic and robot-assisted laparoscopic digestive surgery: present and future directions. World J Gastroenterol. 2016;22(6):1975–2004.View ArticlePubMedPubMed CentralGoogle Scholar
- Baek JH, McKenzie S, Garcia-Aguilar J, Pigazzi A. Oncologic outcomes of robotic-assisted total mesorectal excision for the treatment of rectal cancer. Ann Surg. 2010;251(5):882–6.View ArticlePubMedGoogle Scholar
- Wang B, Tu J, Yin J, Zou C, Wang J, Huang G, Xie X, Shen J. Development and validation of a pretreatment prognostic index to predict death and lung metastases in extremity osteosarcoma. Oncotarget. 2015;6(35):38348–59.PubMedPubMed CentralGoogle Scholar
- Doita M, Harada T, Iguchi T, Sumi M, Sha H, Yoshiya S, Kurosaka M. Total sacrectomy and reconstruction for sacral tumors. Spine. 2003;28(15):E296–301.PubMedGoogle Scholar
- Hsieh PC, Xu R, Sciubba DM, MJ MG, Nelson C, Witham TF, Wolinksy JP, Gokaslan ZL. Long-term clinical outcomes following en bloc resections for sacral chordomas and chondrosarcomas: a series of twenty consecutive patients. Spine. 2009;34(20):2233–9.View ArticlePubMedGoogle Scholar
- Zang J, Guo W, Yang R, Tang X, Li D. Is total en bloc sacrectomy using a posterior-only approach feasible and safe for patients with malignant sacral tumors? J Neurosurg Spine. 2015;22(6):563–70.View ArticlePubMedGoogle Scholar
- Chen Y, Xu H, Li Y, Li J, Wang D, Yuan J, Liang Z. Laparoscopic resection of presacral teratomas. J Minim Invasive Gynecol. 2008;15(5):649–51.View ArticlePubMedGoogle Scholar
- Kohler C, Kuhne-Heid R, Klemm P, Tozzi R, Schneider A. Resection of presacral ganglioneurofibroma by laparoscopy. Surg Endosc. 2003;17(9):1499.View ArticlePubMedGoogle Scholar
- Bax NM, van der Zee DC. The laparoscopic approach to sacrococcygeal teratomas. Surg Endosc. 2004;18(1):128–30.View ArticlePubMedGoogle Scholar
- Possover M, Kostov P. Laparoscopic management of sacral nerve root schwannoma with intractable vulvococcygodynia: report of three cases and review of literature. J Minim Invasive Gynecol. 2013;20(3):394–7.View ArticlePubMedGoogle Scholar
- Song JY, Kim SY, Park EG, Kim CJ, Kim DG, Lee HK, Park IY. Schwannoma in the retroperitoneum. J Obstet Gynaecol Res. 2007;33(3):371–5.View ArticlePubMedGoogle Scholar